Serology in COVID-19: Comparison of Two Methods

Anna Moniuszko-Malinowska, Wojciech Jelski, Justyna Dunaj, Barbara Mroczko, Piotr Czupryna, Ewelina Kruszewska and Sławomir Pancewicz
Additional contact information
Anna Moniuszko-Malinowska: Department of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland
Wojciech Jelski: Department of Biochemical Diagnostics, Medical University in Bialystok, Jerzego Waszyngtona 15A, 15-269 Białystok, Poland
Justyna Dunaj: Department of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland
Barbara Mroczko: Department of Biochemical Diagnostics, Medical University in Bialystok, Jerzego Waszyngtona 15A, 15-269 Białystok, Poland
Piotr Czupryna: Department of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland
Ewelina Kruszewska: Department of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland
Sławomir Pancewicz: Department of Infectious Diseases, Neuroinfections Medical University in Bialystok, Żurawia 14, 15-540 Białystok, Poland

IJERPH, 2021, vol. 18, issue 12, 1-4

Abstract: Background: The aim of our study was to examine the performance of two assays in detecting SARS-CoV-2 antibodies. Methods: A total of 127 COVID-19 disease contacts from the Infectious Diseases Department were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) and LIAISON ® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin). Results: The assays exhibited a 96.85% (123/127 patients) test result agreement. In two cases, the positive results obtained by SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) were negative based on the LIAISON ® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test, and in two cases, negative results from the LIAISON ® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test were positive with the SARS-CoV-2 IgG CMIA on the Alinity system (Abbott). Conclusions: Based on the results of our study, we conclude that in population medicine, the assessments of anti-SARS-CoV-2 antibodies after exposure to SARS-CoV-2 virus based on spike protein or nucleocapsid protein show comparable effectiveness.

Keywords: SARS-CoV-2; chemiluminescent immunoassay; serology; spike protein; nucleocapsid protein (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/12/6497/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/12/6497/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:12:p:6497-:d:575945

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().